TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications

Citation
Jang, J. Y., S. Kim, E. K. Cho, S. W. Jeong, E. J. Park, W. C. Lee, S. H. Lee, et al. 2014. “TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications.” PLoS ONE 9 (6): e98171. doi:10.1371/journal.pone.0098171. http://dx.doi.org/10.1371/journal.pone.0098171.

Published Version
doi:10.1371/journal.pone.0098171

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406700

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications

Jae Young Jang1, Seong-Jun Kim4, Eun Kyung Cho1, Soung Won Jeong1, Eui Ju Park1, Woong Cheul Lee1, Sae Hwan Lee2, Sang Gyune Kim3, Young Seok Kim3, Hong Soo Kim2, Boo Sung Kim1, Wenyu Lin5, Raymond T. Chung5

1 Institute for Digestive Research, Digestive Disease Center, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Seoul, South Korea,
2 Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, South Korea,
3 Department of Internal Medicine, College of Medicine, Soonchunhyang University, Bucheon, South Korea,
4 Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, California, United States of America,
5 Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Hepatitis C virus (HCV) infection causes chronic liver diseases leading to hepatocellular carcinoma (HCC) and liver failure. We have previously shown that HCV sensitizes hepatocytes to mitochondrial apoptosis via the TRAIL death receptors DR4 and DR5. Although TRAIL and its receptors are selective targets for cancer therapy, their potential against HCC with chronic HCV infection has not been explored yet. Here we show that HCV induces DR4/DR5-dependent activation of caspase-8 leading to elevation of apoptotic signaling in infected cells and also present TRAIL effect in HCV-induced apoptotic signaling. HCV-induced proteolytic cleavage of caspase-9 by stimulating DR4 and DR5, resulting in subsequent cleavage of caspase-3. Further, HCV-induced proteolytic cleavage in caspase-8, caspase-9, and caspase-3 was enhanced in the presence of recombinant TRAIL. HCV-induced cleavage in caspase-9 and increase in caspase-3/7 activity was completely suppressed by silencing of either DR4 or DR5. Perturbing DR4/DR5-caspase-8 signaling complex by silencing DR4 and DR5 or by chemical inhibitor specific to caspase-8 led to decrease of HCV-induced cleavage of poly(ADP-ribose) polymerase (PARP), a substrate for caspase-3 during apoptosis, indicating the functional role of caspase-8 in HCV-induced apoptotic signaling network. Furthermore, TRAIL enhanced PARP cleavage in apoptotic response induced by HCV infection, indicating the effect of TRAIL for the induction of selective apoptosis of HCC cells infected with HCV. Given the importance of apoptosis in HCC development, our data suggest that HCV-induced DR4 and DR5 may be considered as an attractive target for TRAIL therapy against HCC with chronic HCV infection.

Citation: Jang JY, Kim S-J, Cho EK, Jeong SW, Park EJ, et al. (2014) TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications. PLoS ONE 9(6): e98171. doi:10.1371/journal.pone.0098171

Editor: Stephen J. Polyak, University of Washington, United States of America

Received February 3, 2014; Accepted April 29, 2014; Published June 13, 2014

Copyright: © 2014 Jang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MOE) (No. Grant Number: NRF-2011-0010229) and NIH AI069939 (R.T.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: rtsung@partners.org

† These authors contributed equally to this work.

Introduction

Hepatitis C virus (HCV) infects about 170 million people worldwide [1–4]. In the course of persistent infection, inflammation forms the pathogenetic basis of chronic hepatitis that can lead to fibrosis, which can progress to cirrhosis and, eventually, hepatocellular carcinoma [5]. It has been suggested that dysregulation of the apoptotic process in infected cells might be crucial for establishing chronicity, the failure of antiviral treatment, fibrosis progression, and neoplastic transformation [6].

Regulation of apoptosis is complex and mainly triggered by the activation of so-called death receptors [7–9]. These receptors include cluster of differentiation 95 (CD95)/Fas, tumor necrosis factor (TNF)-receptor-1, and TNF-related-apoptosis-inducing-ligand receptors (TRAIL-R) 1 and 2. In contrast to TNF-R1 and CD95/Fas, TRAIL-R1 and -R2, also known as death receptors 4 (DR4) and 5 (DR5), induce apoptosis only in infected or transformed tumor cells [10], but not in uninfected healthy hepatocytes in vivo [11,12].

In addition to inducing apoptosis, these death receptors initiate independent intracellular signaling cascades through mitochondrial dysfunction. Mitochondrial dysfunction plays a critical role in integrating death receptor-initiated apoptosis into a final common pathway by activating a caspase-dependent apoptosis [13–16]. TRAIL binding causes the formation of death-inducing signaling complex, resulting in the activation of caspase-8. Active caspase-8 can trigger direct activation of caspase-3 and cleavage of Bid, followed by mitochondria-dependent activation of caspase-9 via cytochrome C release and apoptotic protease activating factor-1 (Apaf-1) activation [17]. However, the mechanism by which
caspases is activated is still not well defined in hepatitis C virus infection.

We recently demonstrated that co-infection with HCV and HIV stimulates DR4 and DR5 gene expression and subsequently activates caspase-3 signaling pathway, resulting in induction of mitochondrial apoptosis of human hepatocytes [18]. In this study, we demonstrate the significant contribution of caspase-8 activation to HCV-induced DR4/DR5-dependent hepatocyte apoptosis.

Materials and Methods

Cell culture and virus

The human hepatocellular carcinoma Huh7.5.1 cells used in this study were grown in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone) supplemented with 10% fetal bovine serum (HyClone; Thermo Fisher Scientific, Wilmington, Delaware, USA), 100 U/ml penicillin and 0.1 mg/ml streptomycin (HyClone; Thermo Fisher Scientific, Wilmington, Delaware, USA). Cell culture-derived HCV-JFH-1 (HCVcc) used in this study was propagated and prepared, as described previously [18].

Reagents and antibodies

Recombinant human TRAIL, pan-caspase inhibitor Z-VAD-FMK, caspase-8 specific inhibitor Z-IETD-FMK, and caspase-9 specific inhibitor Z-LEHD-FMK used in this study were purchased from R&D systems (Abingdon). TRAIL and caspase inhibitors were reconstituted according to the manufacturer’s instructions. Primary antibodies used in this study include the following: rabbit monoclonal anti-cleaved PARP (Cell signaling Technology); mouse monoclonal anti-DR4 (Abcam); rabbit monoclonal anti-DR5 (Cell signaling Technology); rabbit monoclonal anti-cleaved caspase-3 (Cell signaling Technology); rabbit monoclonal anti-cleaved caspase-8 (Cell signaling Technology); rabbit monoclonal anti-cleaved caspase-9 (Cell signaling Technology); rabbit monoclonal anti-cleaved Bid (Invitrogen); mouse monoclonal anti-HCV core (Thermo Fisher Scientific); mouse monoclonal anti-β-actin (Sigma); mouse monoclonal anti-β-actin (Sigma). The secondary antibodies used for Western blot analysis were HRP-conjugated anti-mouse IgG (Santa Cruz Biotechnology) and HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology).

Small interfering RNA transfection

siGENOME non-targeting siRNA pool #1 and ON-TARGETplus SMARTpool small interfering RNA (siRNA) for DR4 (NM_003844) and DR5 (NM_003842) were purchased from Dharmacon. Huh7.5.1 cells were transfected with siRNAs (50 nM) using Lipofectamine RNAiMAX transfection reagent according to the manufacturer’s instructions (Invitrogen) prior to HCVcc infection.

Real-time qRT-PCR

To analyze the expression levels of DR4 and DR5, total cellular RNA was extracted from Huh7.5.1 cells using RNeasy Mini kit (Qiagen) and subsequently, complementary DNA was synthesized by using GeneAmp RNA PCR kit (Applied Biosystems) according to the manufacturer’s instructions. Power SYBR Green PCR Master Mix (Applied Biosystems) was used to quantify the cellular RNA levels. The following primer sets were used for RT-PCR: DR4 forward, 5’-CTGACGCAAGCGCACCTCGCTGTCCAC; DR4 reverse, 5’-TCAAGGAGCAGCGGACAGCTGCAG; DR5 forward, 5’-GGGAGGCCCCTCTTGAAGAGGTG; DR5 reverse, 5’-GGGAACTGCTCTCCAGCAGGCTTC; GNB2L1 forward, 5’-GACCATCTGATGGAAGCTTGC; GNB2L1 reverse, 5’-CCGTTGTGAGATCCAGAG. GNB2L1 was used as an internal control. Real-time qPCR was conducted by using a StepOnePlus Real-Time PCR System (Applied Biosystems).

Western blot analysis

Cells were resuspended in lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% Triton X-100, 150 mM NaCl, and 10 μg/ml aprotonin) supplemented with protease inhibitor cocktail (Roche). Whole cell lysates were subjected to SDS-PAGE, transferred to nitrocellulose membrane (Millipore), and Western blot analyzed with antibodies against the indicated proteins.

Caspase-3/7 activity assay

Caspase-3/7 activity in HCV-infected cells was measured using the Caspase-Glo 3/7 assay kit according to the manufacturer’s instruction (Promega). Briefly, Huh7.5.1 cells transfected with non-targeting (NT) or specific-targeting siRNA pools for DR4 and DR5 were infected with HCVcc. At 3 days post-infection, caspase-
specific luminescence activity was measured using a Synergy 2 Multi-Mode Microplate Reader (BioTek).

Statistical analysis
Statistical analysis was performed using a paired student’s t-test. Results were expressed as means ± standard deviation of at least three sample replicates.

Results
HCV infection stimulates DR4 and DR5 gene expression
We have recently shown that HCV infection activates DR4 and DR5-mediated intrinsic apoptotic signaling in human hepatocytes [18], consistent with other reports [19–21]. To evaluate critical determinants on DR4/DR5-dependent apoptotic signaling network induced by HCV infection, we first examined DR4 and DR5 gene expression. As shown in Figs. 1A and B, HCV infection stimulated the level of both DR4 and DR5 mRNA expression, consistent with previous reports [18,19], and induced consistent increase in DR4 and DR5 protein expression as evidenced by Western blotting with antibodies specific to DR4 and DR5 (Fig. 1C). These results indicate that HCV infection stimulates DR4 and DR5 gene expression to promote DR4/DR5-dependent apoptotic signaling.

HCV infection activates caspase-8-dependent apoptosis signaling by stimulating DR4 and DR5
TRAIL induces the recruitment of Fas-associated death domain and procaspase-8 to DR4 and DR5, leading to activation of caspase-8 and subsequent caspase-9/-3-dependent apoptotic signaling pathway [22–25]. To investigate caspase-8-mediated apoptotic signaling by stimulating DR4 and DR5 induced by HCV infection, we analyzed whether HCV induces caspase-8 activation leading to subsequent cleavage in caspase-9 and caspase-3 in Huh7.5.1 cells. As shown in Fig. 2A, HCV infection increased the level of cleaved caspase-9 and caspase-3 in Huh7.5.1 cells. Huh7.5.1 cells transfected with non-targeting (NT) or gene-specific (ST) siRNA pools targeting DR4 and DR5, respectively, were infected with HCVcc at 3 days post-infection, the mRNA levels of DR4 and DR5 were analyzed by real-time qRT-PCR (B) (mean ± SD; n = 3; *p < 0.05, **p < 0.01) and whole cell lysates were analyzed by Western blotting with antibodies specific to the indicated proteins (C). The activity of caspase-3/7 was measured according to manufacturer’s instructions (mean ± SD; n = 3; *p < 0.005). doi:10.1371/journal.pone.0098171.g002
Consistent with previous results, HCV infection led to Bax activation, a key mediator of apoptosis, in Huh7.5.1 cells (Fig. 2A) [26]. HCV infection also increased caspase-3/7 activity in Huh7.5.1 cells (Fig. 2C). Further, we examined the significance of DR4 and DR5 on apoptotic signaling pathway activated by HCV infection. As shown in Figs. 2C and D, HCV-induced caspase-9 cleavage and increase in caspase-3/7 activity was inhibited by silencing either DR4 or DR5 as evidenced by qRT-PCR (Fig. 2B). Together, these results indicate that caspase-8 activation via DR4 and DR5 is required to promote HCV-induced apoptotic signaling.

HCV infection elevates DR4/DR5-mediated PARP cleavage via caspase-8 activation

PARP cleavage by caspase activation is a hallmark of apoptosis [27,28]. Thus, we investigated proteolytic cleavage of PARP via DR4/DR5-mediated caspase activation in HCV-infected Huh7.5.1 cells. As shown in Fig. 3A, a notable increase in cleaved PARP level was detected in HCV-infected cells compared to uninfected cells (see lane 3). This increase was further augmented by treatment with recombinant TRAIL (Fig. 3A, lane 6), suggesting that TRAIL may induce enhanced apoptosis via DR4 and DR5 receptors of HCV-infected cells. Interference of caspase-8-mediated apoptotic signaling network by silencing either DR4 or DR5 prevented HCV-induced PARP cleavage (Fig. 3B). Next, we examined whether HCV-induced PARP cleavage is mediated by caspase-8 activation using caspase inhibitors specific to caspase-1/3, caspase-8, and caspase-9, respectively. As shown in Fig. 3C, HCV-induced increase in cleaved PARP was suppressed by inhibiting caspase activity. Here, we note that caspase-8 activation, an upstream effector of caspase-9 and caspase-3, mediates DR4/DR5-mediated PARP cleavage in HCV-infected cells. We also analyzed that HCV-induced PARP cleavage is dose-dependently promoted by TRAIL treatment (Fig. 3D). By inhibiting caspase-8 activity, the functional significance of caspase-8 for DR4/DR5-dependent apoptotic signaling in HCV-infected cells was revealed through suppression of HCV-induced Bid cleavage and subsequent caspase-9 cleavage (Fig 4). Caspase-8 activation promotes cleavage of Bid and subsequent translocation of truncated Bid to

Figure 3. HCV-induced DR4/DR5-mediated caspase-8 activity affects PARP cleavage. (A) Western blot analysis of cleaved PARP in HCV-infected cells. Whole cell lysates extracted from HCV-infected Huh7.5.1 cells grown in the absence or presence of recombinant TRAIL (100 ng/ml) were analyzed by Western blotting with antibodies specific to the indicated proteins. (B) Huh7.5.1 cells transfected with non-targeting (NT) or gene-specific (ST) siRNA pools targeting DR4 and DR5, respectively, were infected with HCVcc. At 3 days post-infection, whole cell lysates were analyzed by Western blotting with antibodies specific to the indicated proteins. (C) HCV-infected Huh7.5.1 cells stimulated with recombinant TRAIL (100 ng/ml) were treated with Z-VAD-FMK (pan inhibitor; 40 μM), Z-IETD-FMK (caspase-8 inhibitor; 40 μM), and Z-LEHD-FMK (caspase-9 inhibitor; 40 μM), respectively, for 72 h before harvest. The expression level of PARP was analyzed by Western blotting with anti-cleaved PARP antibody. (D) Western blot analysis showing dose-dependent effects of recombinant TRAIL on PARP cleavage in HCV-infected cells. HCV-infected Huh7.5.1 cells were treated with recombinant TRAIL for 72 h at the indicated dose points. Whole cell lysates were analyzed by Western blotting with anti-cleaved PARP antibody. Samples: MC, media control. (A-D) β-actin was used as an internal loading control.

doi:10.1371/journal.pone.0098171.g003

Figure 4. HCV-induced caspase-8 activity modulates caspase-9 cleavage. Huh7.5.1 cells were infected with HCVcc in the absence or presence of caspase-8 inhibitor (20 μM) for 72 h before harvest. The expression levels of truncated Bid (t-Bid) and cleaved caspase-9 were analyzed by Western blotting with antibodies specific to t-Bid and cleaved caspase-9. α-tubulin was used as an internal loading control. The relative intensity of t-Bid and cleaved caspase-9 normalized to α-tubulin was analyzed by ImageJ. Samples: MC, media control.

doi:10.1371/journal.pone.0098171.g004
the mitochondria, eventually resulting in apoptosis via induction of cytochrome C release [17,29]. Together, these results demonstrate that HCV infection promotes DR4/DR5-mediated PARP cleavage via translocation of caspase 8-truncated Bid.

**Discussion**

Apoptosis, or programmed cell death, is a process in which cells activate intracellular death pathways to terminate themselves systematically in response to a wide variety of stimuli [30,31]. Previous studies have shown that the severity of liver damage in chronic HCV is associated with the degree of hepatocyte apoptosis [32,33]. However, the contribution of apoptosis or the molecular mechanisms that cause liver cell damage during HCV infection have not yet been clearly defined. Recently, death receptor DR4/DR5 has been recognized as a specific mediator of HCV-induced hepatocyte apoptosis [34–36]. Thus, we sought to evaluate critical determinants, particularly caspase-8 activation, of the DR4/DR5-dependent apoptotic signaling pathway induced by HCV infection.

A therapeutic potential of TRAIL for liver cancer with persistent HCV infection has been overlooked. TRAIL receptors including DR4 and DR5 are very attractive targets for cancer therapy [37]. Hence, in this work, our research purpose was (1) to examine the role of caspase-8, one of important determinants of DR4/DR5-mediated apoptosis signaling network during HCV infection as well as (2) to illuminate the possibility of TRAIL use for therapy of hepatocellular carcinoma caused by HCV infection.

It is commonly assumed that virus clearance requires the destruction of infected cells by virus-specific cytotoxic T-lymphocytes via the CD95 receptor, TNF-receptor-1 and TRAIL receptors DR4 and DR5. If death receptor-mediated apoptosis works adequately, it is beneficial for the organism and may lead to elimination of virus-infected cells. However, dysregulation of this system might result in liver damage. Therefore, TRAIL receptors, which selectively kill virus-infected cells while leaving uninfected cells intact, have evolved as a prime physiological mechanism in order to selectively eliminate virus-infected cells [38–40]. We and others have previously shown the stimulation of DR4 and DR5’s in the liver of patients with chronic HCV as well as in HCV-infected cells [11,18,21,39,41]. In contrast, few reports have suggested that HCV infection does not affect DR4 or DR5 expression [20,42]. In this study, we clarify that HCV infection stimulates DR4 and DR5 gene expression at both the transcriptional and translational levels. HCV infection induces TRAIL-mediated mitochondrial apoptosis via caspase-9 activation [20], however, the precise mechanism still remains to be clarified. In Fig. 2, we show that HCV infection induces the activation of caspase-8 and subsequent downstream effectors caspase-9 and caspase-3 in response to TRAIL. The functional significance of DR4 and DR5 in activation of caspase-dependent apoptotic signaling induced by HCV infection was also clarified by reduction of caspase-3/7 activity by DR4 and DR5 silencing (Figs. 2C and D). We propose that HCV infection promotes caspase-8 activity followed by activation of caspase-9 and caspase-3, as evidenced by suppression of DR4/DR5-mediated PARP cleavage via translocation of caspase 8-truncated Bid. Taken together, our data demonstrate the functional significance of DR4/DR5-mediated caspase-8 activation as a critical mediator of HCV-induced apoptosis. Efforts to inhibit the TRAIL apoptotic program may be warranted to retard the progression of HCV-related advanced liver disease.

**Acknowledgments**

We thank Drs. Woo Jin Chung (Dongsan Hospital, Koryung University, Daegu, South Korea) and Eui-Cheol Shin (Korea Advanced Institute of Science and Technology, Daejeon, South Korea) for providing the critical reagents/materials/analysis tools. This work was supported in part by National Research Foundation of Korea Grant NRF-2011-0010229 (to J.Y.J.) and National Institute of Health Grant AI069939 (to R.T.C.).

**Author Contributions**

Conceived and designed the experiments: JYJ SK. Performed the experiments: JYJ EKC. Analyzed the data: JYJ SK JKC. Contributed reagents/materials/analysis tools: JYJ SK JKC. Wrote the paper: SWJ EJP WCL SHL SGK YSK HSK BSK WL RTC. Drafting the article or revising it critically for important intellectual content: SWJ EJP WCL SHL SGK YSK HSK BSK WL RTC. Final approval of the version to be published: JYJ SK JKC.

**References**

1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41–52.
2. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6–9.
3. Harmois DM (2012) Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc 87: 67–78.
4. Jung JY, Chung RT (2010) New treatments for chronic hepatitis C. Korean J Hepatol 16: 263–277.
5. LeBlanc HN, Ashkenazi A (2000) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66–75.
6. Rust C, Gores GJ (2000) Apoptosis and liver disease. Am J Med 108: 567–574.
7. Loyshen RM (2000) Apoptosis and liver disease. Am J Med 108: 567–574.
8. Rust C, Gores GJ (2000) Apoptosis and liver disease. Am J Med 108: 567–574.
9. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770–776.
10. Rust C, Gores GJ (2000) Apoptosis and liver disease. Am J Med 108: 567–574.
Caspase-8 Is Required for Hepatocyte Apoptosis in HCV

15. Thornberry NA (1998) Caspases: key mediators of apoptosis. Chem Biol 5: R97–103.
16. Kumar S (2007) Caspase function in programmed cell death. Cell Death Differ 14: 32–43.
17. Luo X, Budhuradjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 401–490.
18. Jang JY, Skaas RX, Lin W, Weinberg E, Cheng WJ, et al. (2011) HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 54: 612–620.
19. Deng Z, Yan H, Hu J, Zhang S, Peng P, et al. (2012) Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathway. PLoS One 7: e37700.
20. Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, et al. (2008) Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol 181: 4926–4935.
21. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, et al. (2007) Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133: 1649–1659.
22. Sprick MR, Weigand MA, Risser E, Rauch CT, Juo P, et al. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599–609.
23. Pan G, Ni J, Wei YF, Yu G, Geng Z, et al. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815–818.
24. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, et al. (1997) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 57: 3976–3985.
25. Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, et al. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801–809.
26. Li H, Zuo H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501.
27. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818–821.
28. Song JJ, Lee YJ (2008) Differential cleavage of Mast by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal 20: 892–906.
29. Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, et al. (2008) Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol 82: 10375–10385.
30. Kauffmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poizier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976–3985.
31. Kanzler S, Galle PR (2000) Apoptosis and the liver. Semin Cancer Biol 10: 173–184.
32. Calabrese F, Pinton P, Pettenazzo E, Benvegnu L, Vario A, et al. (2000) Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31: 1153–1159.
33. Bantel H, Schulze-Osthoff K (2003) Apoptosis in hepatitis C virus infection. Cell Death Differ 10 Suppl 1: S48–58.
34. Pianko S, Patelia S, Oostapowicz G, Desmond P, Sievert W (2001) Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrotic mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 8: 406–413.
35. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreiro-Otero R, Alonso JL, et al. (1994) Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 179: 841–848.
36. Tao S, Hayashi N, Mita E, Ueda K, Moehizuki K, et al. (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29: 517–523.
37. Wierzek J, Holland P, Graves J (2010) Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16: 1701–1708.
38. Sedger LM, Shoue DM, Blanton RA, Peschon JJ, Goodwin RG, et al. (1999) IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 163: 926–926.
39. Walczak H, Miller RE, Artail K, Glimak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157–163.
40. Munuth B, Wirth T, Zender L, Waltermath M, Trauwrein C, et al. (2005) Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54: 1590–1596.
41. Saijou Y, Shiraki K, Fuke H, Inoue T, Miyashita K, et al. (2005) Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases. Hum Pathol 36: 1066–1073.
42. Munuth B, Kuhnel F, Zender L, Paul Y, Tillmann H, et al. (2003) Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17: 94–96.
43. Masuoka HC, Gucicardi ME, Gores GJ (2009) Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 13: 467–475.
44. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305–1308.
45. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME (1998) Apoptosis signaling by death receptors. Eur J Biochem 254: 439–459.
46. Bantel H, Lugering A, Poremba C, Lugering N, Held J, et al. (2003) Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34: 758–767.